Cure My Disease

Don't miss your cure!

 Log in / Sign up

New weapon tested in fight against advanced cancers

NCT ID NCT05356741

Recruiting now Disease control Sponsor: Vir Biotechnology, Inc. Source: ClinicalTrials.gov ↗

Summary

This early-stage trial is testing a new drug called VIR-5818, both by itself and combined with an existing immunotherapy (pembrolizumab), in people with advanced HER2-positive cancers that have spread. The main goals are to find safe doses and see how the body processes the drug, while also checking for early signs that it might help shrink tumors. It will enroll about 645 participants with various types of advanced cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC HER2-EXPRESSING CANCERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Investigational site number #100

    RECRUITING

    Melbourne, Victoria, 3000, Australia

  • Investigational site number #101

    RECRUITING

    Randwick, 2031, Australia

  • Investigational site number #150

    RECRUITING

    Toulouse, 31059, France

  • Investigational site number #200

    RECRUITING

    Porto, 4200-072, Portugal

  • Investigational site number #250

    RECRUITING

    Pamplona, 31008, Spain

  • Investigational site number #251

    RECRUITING

    Barcelona, 08035, Spain

  • Investigational site number #252

    RECRUITING

    Madrid, 28050, Spain

  • Investigational site number #253

    RECRUITING

    Pozuelo de Alarcón, 28223, Spain

  • Investigational site number #254

    RECRUITING

    Madrid, 28027, Spain

  • Investigational site number #255

    RECRUITING

    Barcelona, 08023, Spain

Conditions

Explore the condition pages connected to this study.

LOCALLY ADVANCED OR METASTATIC HER2-EXPRESSING CANCERS